BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Telehealth, also known as telemedicine or e-health, is the healthcare services delivery through remote settings.

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA are pleased to announce NEXTSTELLIS® has been nominated for the 2022 Prix Galien USA Award for Best Pharmaceutical Agent.

CSL Limited is pleased to announce it has now received all necessary regulatory clearances for the acquisition of Vifor Pharma AG announced on 14 December 2021.

Vimian Group has acquired Heiland GmbH, a leading online ordering platform offering veterinary pharmaceuticals and other veterinary products to veterinary clinics across Germany.

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022.

iTeos Therapeutics, Inc. announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs Wide Open – Opportunities and Challenges in Immuno-Oncology” on Tuesday, August 9, 2022 at 8:00 a.m.

Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, announced that Chimerix management will participate in the Targeted Oncology panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 10:20 a.m.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today reported financial results and provided a business update for the second quarter ended June 30, 2022.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that it will release its financial results for the second quarter of 2022 on Wednesday, August 31, 2022.